Involvement of the DNA mismatch repair system in cisplatin sensitivity of testicular germ cell tumours

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Involvement of the DNA mismatch repair system in cisplatin sensitivity of testicular germ cell tumours. / Rudolph, Christiane; Melau, Cecilie; Nielsen, John E.; Jensen, Kristina Vile; Liu, Dekang; Pena-Diaz, Javier; Meyts, Ewa Rajpert-De; Rasmussen, Lene Juel; Jorgensen, Anne.

In: Cellular Oncology, Vol. 40, No. 4, 2017, p. 341-355.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Rudolph, C, Melau, C, Nielsen, JE, Jensen, KV, Liu, D, Pena-Diaz, J, Meyts, ER-D, Rasmussen, LJ & Jorgensen, A 2017, 'Involvement of the DNA mismatch repair system in cisplatin sensitivity of testicular germ cell tumours', Cellular Oncology, vol. 40, no. 4, pp. 341-355. https://doi.org/10.1007/s13402-017-0326-8

APA

Rudolph, C., Melau, C., Nielsen, J. E., Jensen, K. V., Liu, D., Pena-Diaz, J., ... Jorgensen, A. (2017). Involvement of the DNA mismatch repair system in cisplatin sensitivity of testicular germ cell tumours. Cellular Oncology, 40(4), 341-355. https://doi.org/10.1007/s13402-017-0326-8

Vancouver

Rudolph C, Melau C, Nielsen JE, Jensen KV, Liu D, Pena-Diaz J et al. Involvement of the DNA mismatch repair system in cisplatin sensitivity of testicular germ cell tumours. Cellular Oncology. 2017;40(4):341-355. https://doi.org/10.1007/s13402-017-0326-8

Author

Rudolph, Christiane ; Melau, Cecilie ; Nielsen, John E. ; Jensen, Kristina Vile ; Liu, Dekang ; Pena-Diaz, Javier ; Meyts, Ewa Rajpert-De ; Rasmussen, Lene Juel ; Jorgensen, Anne. / Involvement of the DNA mismatch repair system in cisplatin sensitivity of testicular germ cell tumours. In: Cellular Oncology. 2017 ; Vol. 40, No. 4. pp. 341-355.

Bibtex

@article{99894dc2164a4e76af0b9f1ae57c48b4,
title = "Involvement of the DNA mismatch repair system in cisplatin sensitivity of testicular germ cell tumours",
abstract = "BackgroundTesticular germ cell tumours (TGCT) are highly sensitive to cisplatin-based chemotherapy, but patients with tumours containing differentiated teratoma components are less responsive to this treatment. The cisplatin sensitivity in TGCT has previously been linked to the embryonic phenotype in the majority of tumours, although the underlying mechanism largely remains to be elucidated. The aim of this study was to investigate the role of the DNA mismatch repair (MMR) system in the cisplatin sensitivity of TGCT.MethodsThe expression pattern of key MMR proteins, including MSH2, MSH6, MLH1 and PMS2, were investigated during testis development and in the pathogenesis of TGCT, including germ cell neoplasia in situ (GCNIS). The TGCT-derived cell line NTera2 was differentiated using retinoic acid (10 μM, 6 days) after which MMR protein expression and activity, as well as cisplatin sensitivity, were investigated in both undifferentiated and differentiated cells. Finally, the expression of MSH2 was knocked down by siRNA in NTera2 cells after which the effect on cisplatin sensitivity was examined.ResultsMMR proteins were expressed in proliferating cells in the testes, while in malignant germ cells MMR protein expression was found to coincide with the expression of the pluripotency factor OCT4, with no or low expression in the more differentiated yolk sac tumours, choriocarcinomas and teratomas. In differentiated NTera2 cells we found a significantly (p < 0.05) lower expression of the MMR and pluripotency factors, as well as a reduced MMR activity and cisplatin sensitivity, compared to undifferentiated NTera2 cells. Also, we found that partial knockdown of MSH2 expression in undifferentiated NTera2 cells resulted in a significantly (p < 0.001) reduced cisplatin sensitivity.ConclusionThis study reports, for the first time, expression of the MMR system in fetal gonocytes, from which GCNIS cells are derived. Our findings in primary TGCT specimens and TGCT-derived cells suggest that a reduced sensitivity to cisplatin in differentiated TGCT components could result from a reduced expression of MMR proteins, in particular MSH2 and MLH1, which are involved in the recognition of cisplatin adducts and in activation of the DNA damage response pathway to initiate apoptosis.",
keywords = "Mismatch repair, Germcell neoplasia, Testicular cancer, Pluripotency, Cisplatin",
author = "Christiane Rudolph and Cecilie Melau and Nielsen, {John E.} and Jensen, {Kristina Vile} and Dekang Liu and Javier Pena-Diaz and Meyts, {Ewa Rajpert-De} and Rasmussen, {Lene Juel} and Anne Jorgensen",
year = "2017",
doi = "10.1007/s13402-017-0326-8",
language = "English",
volume = "40",
pages = "341--355",
journal = "Cellular Oncology",
issn = "2211-3428",
publisher = "Springer",
number = "4",

}

RIS

TY - JOUR

T1 - Involvement of the DNA mismatch repair system in cisplatin sensitivity of testicular germ cell tumours

AU - Rudolph, Christiane

AU - Melau, Cecilie

AU - Nielsen, John E.

AU - Jensen, Kristina Vile

AU - Liu, Dekang

AU - Pena-Diaz, Javier

AU - Meyts, Ewa Rajpert-De

AU - Rasmussen, Lene Juel

AU - Jorgensen, Anne

PY - 2017

Y1 - 2017

N2 - BackgroundTesticular germ cell tumours (TGCT) are highly sensitive to cisplatin-based chemotherapy, but patients with tumours containing differentiated teratoma components are less responsive to this treatment. The cisplatin sensitivity in TGCT has previously been linked to the embryonic phenotype in the majority of tumours, although the underlying mechanism largely remains to be elucidated. The aim of this study was to investigate the role of the DNA mismatch repair (MMR) system in the cisplatin sensitivity of TGCT.MethodsThe expression pattern of key MMR proteins, including MSH2, MSH6, MLH1 and PMS2, were investigated during testis development and in the pathogenesis of TGCT, including germ cell neoplasia in situ (GCNIS). The TGCT-derived cell line NTera2 was differentiated using retinoic acid (10 μM, 6 days) after which MMR protein expression and activity, as well as cisplatin sensitivity, were investigated in both undifferentiated and differentiated cells. Finally, the expression of MSH2 was knocked down by siRNA in NTera2 cells after which the effect on cisplatin sensitivity was examined.ResultsMMR proteins were expressed in proliferating cells in the testes, while in malignant germ cells MMR protein expression was found to coincide with the expression of the pluripotency factor OCT4, with no or low expression in the more differentiated yolk sac tumours, choriocarcinomas and teratomas. In differentiated NTera2 cells we found a significantly (p < 0.05) lower expression of the MMR and pluripotency factors, as well as a reduced MMR activity and cisplatin sensitivity, compared to undifferentiated NTera2 cells. Also, we found that partial knockdown of MSH2 expression in undifferentiated NTera2 cells resulted in a significantly (p < 0.001) reduced cisplatin sensitivity.ConclusionThis study reports, for the first time, expression of the MMR system in fetal gonocytes, from which GCNIS cells are derived. Our findings in primary TGCT specimens and TGCT-derived cells suggest that a reduced sensitivity to cisplatin in differentiated TGCT components could result from a reduced expression of MMR proteins, in particular MSH2 and MLH1, which are involved in the recognition of cisplatin adducts and in activation of the DNA damage response pathway to initiate apoptosis.

AB - BackgroundTesticular germ cell tumours (TGCT) are highly sensitive to cisplatin-based chemotherapy, but patients with tumours containing differentiated teratoma components are less responsive to this treatment. The cisplatin sensitivity in TGCT has previously been linked to the embryonic phenotype in the majority of tumours, although the underlying mechanism largely remains to be elucidated. The aim of this study was to investigate the role of the DNA mismatch repair (MMR) system in the cisplatin sensitivity of TGCT.MethodsThe expression pattern of key MMR proteins, including MSH2, MSH6, MLH1 and PMS2, were investigated during testis development and in the pathogenesis of TGCT, including germ cell neoplasia in situ (GCNIS). The TGCT-derived cell line NTera2 was differentiated using retinoic acid (10 μM, 6 days) after which MMR protein expression and activity, as well as cisplatin sensitivity, were investigated in both undifferentiated and differentiated cells. Finally, the expression of MSH2 was knocked down by siRNA in NTera2 cells after which the effect on cisplatin sensitivity was examined.ResultsMMR proteins were expressed in proliferating cells in the testes, while in malignant germ cells MMR protein expression was found to coincide with the expression of the pluripotency factor OCT4, with no or low expression in the more differentiated yolk sac tumours, choriocarcinomas and teratomas. In differentiated NTera2 cells we found a significantly (p < 0.05) lower expression of the MMR and pluripotency factors, as well as a reduced MMR activity and cisplatin sensitivity, compared to undifferentiated NTera2 cells. Also, we found that partial knockdown of MSH2 expression in undifferentiated NTera2 cells resulted in a significantly (p < 0.001) reduced cisplatin sensitivity.ConclusionThis study reports, for the first time, expression of the MMR system in fetal gonocytes, from which GCNIS cells are derived. Our findings in primary TGCT specimens and TGCT-derived cells suggest that a reduced sensitivity to cisplatin in differentiated TGCT components could result from a reduced expression of MMR proteins, in particular MSH2 and MLH1, which are involved in the recognition of cisplatin adducts and in activation of the DNA damage response pathway to initiate apoptosis.

KW - Mismatch repair

KW - Germcell neoplasia

KW - Testicular cancer

KW - Pluripotency

KW - Cisplatin

U2 - 10.1007/s13402-017-0326-8

DO - 10.1007/s13402-017-0326-8

M3 - Journal article

C2 - 28536927

VL - 40

SP - 341

EP - 355

JO - Cellular Oncology

JF - Cellular Oncology

SN - 2211-3428

IS - 4

ER -

ID: 183011469